Open-Label Extension Study Of Safety And Tolerability Of Pregabalin In Pediatric Patients With Partial-Onset Seizures
NCT ID: NCT00448916
Last Updated: 2021-01-25
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
54 participants
INTERVENTIONAL
2007-05-31
2013-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety, Tolerability, and Pharmacokinetic Study of Pregabalin in Pediatric Patients With Partial Onset Seizures
NCT00437281
A 12-Month Study To Evaluate The Safety And Tolerability Of Pregabalin As Add-On Therapy In Pediatric Subjects 1 Month To 16 Years Of Age With Partial Onset Seizures And Pediatric And Adult Subjects 5 To 65 Years Of Age With Primary Generalized Tonic-Clonic Seizures
NCT01463306
A Study of the Efficacy and Safety of Pregabalin as Add-On Therapy for Partial Onset Seizures in Children Ages 4-16 Years
NCT01389596
A Safety, Efficacy, and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric Subjects <4 Years of Age With Partial Onset Seizures.
NCT02072824
Extension Study Of Long-Term Safety And Efficacy Of Pregabalin As Monotherapy (Lyrica) In Patients With Partial Seizures
NCT00596466
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Pregabalin
Orally-administered pregabalin
Pregabalin
Orally-administered pregabalin
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Pregabalin
Orally-administered pregabalin
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* At least 1 seizure per 28 days, on average
* Completion of study A0081074
Exclusion Criteria
* Progressive CNS pathology
* Failure to tolerate pregabalin in study A0081074
1 Month
16 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of South Alabama
Mobile, Alabama, United States
University of South Alabama Department of Neurology
Mobile, Alabama, United States
Phoenix Children's Hospital
Phoenix, Arizona, United States
The Children's Clinica of Jonesboro, P.A
Jonesboro, Arkansas, United States
Clinical Study Centers, L. L. C.
Little Rock, Arkansas, United States
UCSF Neurology Clinic
San Francisco, California, United States
Child Neurology Center of Northwest Florida
Gulf Breeze, Florida, United States
The Office of Sergio J Jacinto, MD
Tampa, Florida, United States
Pediatric Epilepsy & Neurology Specialists
Tampa, Florida, United States
St. John's Clinic
Springfield, Missouri, United States
St. John's Hospital
Springfield, Missouri, United States
Women and Children's Hospital of Buffalo
Buffalo, New York, United States
Duke University Medical Center
Durham, North Carolina, United States
Baylor College of Medicine - Texas Children's Hospital
Houston, Texas, United States
Texas Children's Hospital
Houston, Texas, United States
Road Runner Research, Ltd.
San Antonio, Texas, United States
Antiguo Hospital Civil de Guadalajara Fray Antonio Alcalde
Guadalajara, Jalisco, Mexico
Yonsei University College of Medicine Severance Hospital / Department of Pediatric Neurology
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2010-020731-39
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
A0081075
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.